Although previous studies have demonstrated apoptosis in BCR/ABL-positive CML cells (e.g., K562 cells) treated with low shikonin concentrations (0.2-1 μM) [28], the effects of shikonin on the BCR/ABL signaling pathway have not yet been reported. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.